A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.

@article{Villablanca2016API,
  title={A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.},
  author={Judith G Villablanca and Samuel L. Volchenboum and Hwangeui Cho and Min Ho Kang and Susan L. Cohn and Clarke P Anderson and Araz Marachelian and Susan Groshen and Denice D. Tsao-Wei and Katherine K. Matthay and John M. Maris and Charlotte E Hasenauer and Scarlett Czarnecki and Hollie A Lai and Fariba Goodarzian and Hiro Shimada and C Patrick Reynolds},
  journal={Pediatric blood & cancer},
  year={2016},
  volume={63 8},
  pages={1349-56}
}
BACKGROUND Myeloablative therapy for high-risk neuroblastoma commonly includes melphalan. Increased cellular glutathione (GSH) can mediate melphalan resistance. Buthionine sulfoximine (BSO), a GSH synthesis inhibitor, enhances melphalan activity against neuroblastoma cell lines, providing the rationale for a Phase 1 trial of BSO-melphalan. PROCEDURES… CONTINUE READING